Merck KGaA strikes $3.9bn deal for SpringWorks
Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks Therapeutics.
Under the deal, Merck will pay $47 per share in cash, representing a 26% premium to SpringWorks' average share price over the 20 days leading up to 7 February 2025, the day before media reports of the potential acquisition surfaced.
Based on SpringWorks' cash holdings at the end of 2024, the deal gives the company an enterprise value of approximately $3.4bn.
Headquartered in Darmstadt, Germany, Merck said the acquisition would 'immediately add revenue' and strengthen its oncology pipeline in the 28 April announcement.
The deal will bolster Merck's oncology portfolio with US-based SpringWorks' pipeline of targeted therapies. These include Ogsiveo (nirogacestat), which is approved for treating desmoid tumours; as well as the MEK inhibitor Gomekli (mirdametinib), which was approved in February 2025 for treating neurofibromatosis type 1 (NF1). Ogsiveo generated $172m in sales in 2024, as per the company's financials.
According to projections from GlobalData's Pharma Intelligence Center, Gomekli is projected to generate up to $564m in global sales by 2030 while Ogsiveo sales are expected to reach $1.2bn by the same year.
GlobalData is the parent company of Pharmaceutical Technology.
In a statement, Merck's CEO Belén Garijo said: 'The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position our company as a globally diversified, innovation and technology powerhouse.
'For our healthcare sector, it sharpens the focus on rare tumours, accelerates growth, and strengthens our presence in the US.'
Late-stage talks between the companies were confirmed last week following several months of speculation. Reuters first reported in February 2025 that Merck was exploring a potential deal, triggering a 34% rise in SpringWorks' share price. Merck KGaA acknowledged the discussions at the time but cautioned that there was no certainty that an agreement would be reached.
The acquisition marks the second deal for Merck in the space of a month. At the beginning of April, the company signed a $1.4bn multi-year collaboration with Caris Life Sciences to access novel antibody-drug conjugate (ADC) targets. Under the agreement, Caris will identify tumour-associated targets that Merck will take into preclinical and clinical development. Merck's lead internal ADC candidate M9140 is currently in Phase I trials for colorectal cancer.
Merck expects the SpringWorks acquisition to close in H2 2025, subject to regulatory and customary approvals.
'Beyond this planned transaction, we will continue to explore M&A opportunities across our three complementary business sectors, always with a firm focus on strategic fit, financial robustness, and long-term value creation,' Garijo concluded.
"Merck KGaA strikes $3.9bn deal for SpringWorks" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Evri to hire thousands more couriers after deal with DHL
Evri is set to expand its courier network with a recruitment drive for 5,000 new couriers, as the company looks to compete in the business letter market. The Yorkshire-based parcel firm recently announced a collaboration with DHL's UK ecommerce division, creating one of the UK's largest delivery networks. The addition of these new roles will bring Evri's total number of self-employed couriers to 33,000. These positions will be available across the UK, with a focus on areas such as Plymouth, Bury, Hastings, Dover, and Scarborough. Approximately 1,000 of the new jobs will be permanent, while the remainder will be flexible roles designed to accommodate the increased demand during the summer and other peak delivery periods. Couriers who commit to working five or more days a week, including Saturday and Sunday, are also given the chance to opt in to its revamped 'Evri Plus' scheme, which includes paid holiday and automatic enrolment into a pension scheme. Evri, which was previously part of the Hermes parcel group, was bought by US private equity firm Apollo for around £2.7 billion last year. It announced plans last month to merge with rival DHL's UK ecommerce business to create a combined company set to deliver more than one billion parcels and one billion letters each year. The deal means Evri will enter the UK business letter market for the first time, bolstering its competition to Royal Mail. Evri has spent £32 million on improving its customer service offering and has seen an improvement in its ratings over recent years, but has said there is 'more to do' to improve with customers continuing to report delivery issues. Chief executive Martijn de Lange said: 'We know that service, reliability and quality are critical factors for our clients and consumers, and so by expanding our self-employed network further, we remain focused on delivering in each of those areas.' Couriers typically earn about £20.90 an hour on average, according to Evri. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Evri to hire 5,000 more couriers after agreeing DHL tie-up
Evri is planning to hire 5,000 couriers in a fresh recruitment drive as the parcel giant takes on rivals after entering the business letter market. The Yorkshire-based firm recently announced it was joining forces with DHL's UK ecommerce arm to form one of the country's biggest delivery firms. It said the new roles would bring its total self-employed courier network to 33,000, its highest number. The roles will be available throughout the UK, with a focus on regions including Plymouth, Bury, Hastings, Dover and Scarborough. About 1,000 of the new jobs will be permanent, while the rest are set to be flexible positions to cater to the typically busy summer months and other peak periods for deliveries. Couriers who commit to working five or more days a week, including Saturday and Sunday, are also given the chance to opt in to its revamped 'Evri Plus' scheme, which includes paid holiday and automatic enrolment into a pension scheme. Evri, which was previously part of the Hermes parcel group, was bought by US private equity firm Apollo for around £2.7 billion last year. It announced plans last month to merge with rival DHL's UK ecommerce business to create a combined company set to deliver more than one billion parcels and one billion letters each year. The deal means Evri will enter the UK business letter market for the first time, bolstering its competition to Royal Mail. Evri has spent £32 million on improving its customer service offering and has seen an improvement in its ratings over recent years, but has said there is 'more to do' to improve with customers continuing to report delivery issues. Chief executive Martijn de Lange said: 'We know that service, reliability and quality are critical factors for our clients and consumers, and so by expanding our self-employed network further, we remain focused on delivering in each of those areas.' Couriers typically earn about £20.90 an hour on average, according to Evri.
